Spots Global Cancer Trial Database for zd1839
Every month we try and update this database with for zd1839 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00090675 | Non-Small-Cell ... | ZD1839 | 18 Years - | AstraZeneca | |
| An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | NCT00684385 | Non Small Cell ... Cancer of the H... | ZD1839 | 18 Years - 130 Years | AstraZeneca | |
| Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | NCT00242918 | Prostate Cancer | docetaxel ZD1839 | 18 Years - | Benaroya Research Institute | |
| Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer | NCT00068653 | Lung Cancer | Celecoxib ZD1839 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | NCT00054691 | Skin Cancer | Iressa | 18 Years - | M.D. Anderson Cancer Center | |
| An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | NCT00787410 | Mesothelioma | ZD1839 | 18 Years - | AstraZeneca | |
| Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | NCT00181688 | Ovarian Cancer Peritoneal Carc... Tubal Carcinoma | Iressa (ZD1839) Arimidex (Anast... | 18 Years - | Massachusetts General Hospital | |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | NCT00280787 | Non Small Cell ... | Paclitaxel Carboplatin CPT-11 Pegfilgrastim Conformal radio... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | NCT00787410 | Mesothelioma | ZD1839 | 18 Years - | AstraZeneca | |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | NCT00280787 | Non Small Cell ... | Paclitaxel Carboplatin CPT-11 Pegfilgrastim Conformal radio... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Iressa Study in Patients With Salivary Gland Cancer | NCT00509002 | Salivary Gland ... | Gefitinib | - | M.D. Anderson Cancer Center | |
| Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00090675 | Non-Small-Cell ... | ZD1839 | 18 Years - | AstraZeneca | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer | NCT00502060 | Advanced Tumor | AZD2171 ZD1839 | 18 Years - | AstraZeneca | |
| A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy | NCT00189358 | Ovarian Cancer Cancer of the F... Peritoneal Canc... | ZD1839 tamoxifen | 18 Years - | AGO Study Group | |
| Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00090675 | Non-Small-Cell ... | ZD1839 | 18 Years - | AstraZeneca | |
| Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | NCT00193336 | Lung Cancer | ZD1839 | 18 Years - | SCRI Development Innovations, LLC | |
| Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer | NCT00026299 | Colorectal Canc... | ZD1839 oxaliplatin | 18 Years - | University of Chicago | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center | |
| Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer | NCT00231465 | Non-Small Cell ... | docetaxel (Taxo... ZD1839 | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates | NCT00104728 | Lung Cancer | ZD1839 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | NCT00684385 | Non Small Cell ... Cancer of the H... | ZD1839 | 18 Years - 130 Years | AstraZeneca | |
| Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer | NCT00268346 | Esophageal Canc... | ZD1839 | 18 Years - | Case Comprehensive Cancer Center | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer | NCT00428896 | Breast Cancer | ZD1839 | 18 Years - 75 Years | University Hospital of Crete | |
| A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer | NCT00428896 | Breast Cancer | ZD1839 | 18 Years - 75 Years | University Hospital of Crete | |
| Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | NCT00193336 | Lung Cancer | ZD1839 | 18 Years - | SCRI Development Innovations, LLC | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
